| Document |
Document Title |
|
WO/2022/045306A1 |
One purpose of the present invention is to provide a compound which is capable of enhancing the bonding strength of an adhesive composition, especially the bonding strength thereof to an adherend with low polarity. Another purpose of the...
|
|
WO/2022/045270A1 |
The present invention is a method for purifying a compound or a polymer that includes a step for mixing so as to bring a solution, activated carbon, and an ion exchange resin into contact; the solution is a solution (1) including a hydro...
|
|
WO/2022/040773A1 |
The present disclosure relates to compositions comprising an oil-in-water nano-emulsion dispersed in an external oil phase, methods for the preparation of such compositions as well as uses of such compositions, for example, for delivery ...
|
|
WO/2022/038475A1 |
The current application relates to a topical pharmaceutical composition comprising at least one active agent selected from CBD and THC, solvent, surfactant, optional permeation enhancer, and optional adhesive/polymer. The topical composi...
|
|
WO/2022/038479A1 |
The present disclosure relates to the transdermal administration of nabilone and cannabinoids and derivatives of these compounds, for the treatment and/or prevention and/or control of medical conditions.
|
|
WO/2022/038997A1 |
Provided are a novel and high-purity fluorene derivative and manufacturing method therefor, said fluorene derivative being represented by formula (1) below. (In the formula, Z is a polycyclic aromatic hydrocarbon having three or more bon...
|
|
WO/2022/038412A1 |
Prior art describes methods for making whole-plant extracts from the cannabis plant. Terpenes and cannabinoids are classes of compounds found inherently in those extracts. But, because those extracts contain hundreds of different, and so...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/032268A1 |
A process for the treatment of waste water, spent air, and hydrocarbon containing liquid and gaseous streams in the cumene/phenol complex is described. Various effluent streams are combined in appropriate collection vessels, including a ...
|
|
WO/2022/020942A1 |
The present application relates to the extraction of phytochemicals, more specifically to methods and systems for the selective extraction of phytochemicals from biomass. A method may comprises placing the biomass into a thermal chamber,...
|
|
WO/2022/023510A1 |
The present invention relates to complex non-naturally occurring phenolic compounds mixtures or engineered phenolic compounds compositions, from catalytic degradation of lignocellulose, and the use thereof.
|
|
WO/2022/020944A1 |
Disclosed are methods for synthesizing cannabielsoin (CBE) and or analogs thereof. In particular, the present disclosure provides methods for synthesizing CBE or analogs thereof comprising steps of providing a cannabinoid composition tha...
|
|
WO/2022/016269A1 |
Pharmaceutical formulations and treatments are provided that make combined use of selected antibiotic cannabinoids with silver-containing medicaments. Therapeutically effective regimens are provided that facilitate positive drug-drug int...
|
|
WO/2022/011460A1 |
The present disclosure provides a composition comprising a cannabinoid for administration to a mucosal surface of a subject that, upon administration to the subject, demonstrates improvements compared to known cannabis compositions for e...
|
|
WO/2022/014876A1 |
The present invention relates to a method for decomposing phenolic byproducts, and more specifically, to a method for decomposing phenolic byproducts, which comprises the steps of: feeding a phenolic byproduct stream to a decomposer and ...
|
|
WO/2022/009948A1 |
The present invention is a composition for forming a lithography film, said composition containing at least one substance which is selected from among compounds having a specific structure and resins that are obtained using the compounds...
|
|
WO/2022/010102A1 |
The present invention relates to a method for decomposing phenol-based by-product. More specifically, the present invention provides a method for decomposing phenol-based by-product, the method comprising the steps of: introducing a phen...
|
|
WO/2022/003623A1 |
The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spa...
|
|
WO/2021/261062A1 |
Provided is an aqueous solution having, dissolved therein, 0.3 to 200 mM of a stilbene compound (A) that is a compound represented by formula (1) or a glycoside thereof and 0.3 to 200 mM of a flavin derivative (B) selected from riboflavi...
|
|
WO/2021/256551A1 |
[Problem] To provide: a 4-hydroxystyrene solution that is preferable as a raw material for commercial-scale production of 4-hydroxystyrene-based polymers, and has a high purity and good storage stability; and a production method for the ...
|
|
WO/2021/248251A1 |
The present disclosure relates to the use of suitable phytocannabinoids such as cannabidivarin, cannabinol, cannabigerol or cannabichromene or combinations thereof for treatment of multiple myeloma and/or similar conditions, diseases or ...
|
|
WO/2021/250565A1 |
The present invention relates to an improved process for preparation of Empagliflozin of formula (I). The invention further relates to preparation of crystalline form of Empagliflozin and its particle size having coarser particle or D50 ...
|
|
WO/2021/246408A1 |
Provided are a compound represented by formula 1 or a salt thereof, a medicine, an antidiuretic drug, and a protein kinase A-activating agent. In formula 1, R1-R8 are each independently one selected from the group consisting of H, a line...
|
|
WO/2021/237371A1 |
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...
|
|
WO/2021/237841A1 |
Disclosed is the use of an organic membrane in hemp extraction, involving: subjecting a hemp raw material to extraction with an organic solvent, and then, sequentially carrying out microporous filter membrane filtration and non-porous or...
|
|
WO/2021/238242A1 |
Disclosed in the present invention is the use of full-spectrum hemp oil in the treatment of epilepsy. The full-spectrum hemp oil comprises cannabidivarin (CBDV), cannabigerol (CBG) and cannabidiol (CBD) and does not comprise the addictiv...
|
|
WO/2021/240041A1 |
The present invention relates to a method for extracting the phenol 3,4-dihydroxyphenylglycol (DHPG) present in any part of the plant, products or by-products derived from olive tree or any other plant product of the family Oleaceae, Oro...
|
|
WO/2021/236709A1 |
The present disclosure encompasses solid state forms of Tapinarof, in embodiments crystalline polymorphs or co-crystals of Tapinarof, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/022378A9 |
The current application relates to a composition comprising a cannabis extract and a lipid-based carrier; wherein the lipid-based carrier comprises omega-3 fatty acids and at least one of monoacylglycerides, diacylglycerides, triglycerid...
|
|
WO/2021/228034A1 |
Provided is a preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methylamine or a salt thereof, which uses 4-fluoro-3-methylphenol as the starting material, and is carried out through the steps of bromination, O-alkylation, cyc...
|
|
WO/2021/226725A1 |
Traditional methods of hash production are very labor intensive, and the skills of the individual play a key role in defining the quality of the finished product. Hash production requires multiple steps and lacks automation, and thus, it...
|
|
WO/2021/226711A1 |
Disclosed are methods for preparing carmabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the r...
|
|
WO/2021/217241A1 |
The present disclosure relates to a method for producing a purified cannabaceae biomass extract, wherein a crude alcoholic cannabaceae biomass extract comprising at least two cannabinoid compounds in an alcoholic solvent is circulating t...
|
|
WO/2021/214545A1 |
The current application relates to a transdermal or topical pharmaceutical formulation comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of chronical pain with reduced side effects in the patient. The transder...
|
|
WO/2021/214762A1 |
The invention provides an isolated material, or a phenolate form of at least one phenol- containing active material, wherein the isolated material comprises one or more phenolate species and a counter ion (a cation) in the form of a meta...
|
|
WO/2021/215163A1 |
Provided is a radiation-sensitive resin composition capable of forming a resist pattern having excellent pattern shape. Also provided is a method for forming a resist pattern. This radiation-sensitive resin composition contains: a copoly...
|
|
WO/2021/207850A1 |
The present disclosure relates to water-soluble formulations containing cannabinoids. In particular, the formulations comprise at least one isolated cannabinoid, cannabinoid oil or cannabinoid resin, and a solubilizing agent of Formula (...
|
|
WO/2021/203206A1 |
The formulation includes CBD and a PPAR agonist. The PPAR agonist can be an omega-3 based PPAR agonist and more specifically can comprise substantially equal parts DHA and EPA.
|
|
WO/2021/202986A1 |
The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors,...
|
|
WO/2021/195750A1 |
The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising ad...
|
|
WO/2021/195520A1 |
Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.
|
|
WO/2021/191832A1 |
The present provides a simple, convenient and time-efficient process for the preparation of propofol. Particularly, the present invention provides an improved process for the preparation of propofol using a heterocyclic base for the deca...
|
|
WO/2021/184125A1 |
It is provided an anti-aging composition comprising at least one plant extract and a carrier, the at least one plant extract is at least one of Serenoa repens, Hypericum perforatum, Ilex paraguariensis, Ocimum tenuiflorum, Solidago virga...
|
|
WO/2021/188983A1 |
Described herein are pharmaceutical compositions comprising cannabinoids. In some embodiments, such compositions are useful for the treatment of inflammatory, autoimmune diseases or disorders, cancer, or neurodegenerative diseases. Furth...
|
|
WO/2021/179088A1 |
The present disclosure relates to a composition comprising: i) terpenes in a diamond construction for delivering a specific aroma profile; and ii) optionally, at least one cannabinoid. The present disclosure also relates to methods of us...
|
|
WO/2021/182238A1 |
The present invention improves the dissolution rate of 1,1'-bi-2-naphthol in ethyl acetate. The 1,1'-bi-2-naphthol composition according to an embodiment includes racemic 1,1'-bi-2-naphthol, and toluene and/or chlorotoluene, the Hazen co...
|
|
WO/2021/177343A1 |
Provided is a method in which a caged compound represented by general formula (I) is irradiated with light in the presence of a photosensitizer to thereby release a compound represented by general formula (II). In cases when X is O, th...
|
|
WO/2021/176407A1 |
A method for preparing a solid form of Bisphenol F is disclosed. The method comprises feeding Bisphenol F at a temperature in the range of 130-170 °C into an extruder; processing the fed Bisphenol F in a first mixing zone of the extrude...
|
|
WO/2021/174351A1 |
Particular antimicrobials are identified for efficacy in a composition with DispersinB to enhance biofilm dispersal and inactivation of biofilm embedded bacteria.
|
|
WO/2021/175335A1 |
The present invention relates to an isopaucifloral F phosphate compound and a pharmaceutical use thereof. As verified by experiments, the isopaucifloral F phosphate compound and a pharmaceutically acceptable salt thereof is effective aga...
|
